Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
Authors:
- Anneleen DecockADAnneleen Decock
- Maté OngenaertMOMaté Ongenaert
- Jasmien HoebeeckJHJasmien Hoebeeck
- Katleen De PreterKPKatleen De Preter
- Gert Van PeerGPGert Van Peer
- Wim Van CriekingeWCWim Van Criekinge
- Ruth LadensteinRLRuth Ladenstein
- Johannes H SchulteJSJohannes H Schulte
- Rosa NogueraRNRosa Noguera
- Raymond L StallingsRSRaymond L Stallings
- An Van DammeADAn Van Damme
- Geneviève LaureysGLGeneviève Laureys
Open Access
- 3 October 2012
- journal article
- research article
- Published by Springer Nature in Genome Biology
- Vol. 13 (10) , R95
Abstract
Background: Accurate outcome prediction in neuroblastoma, which is necessary to enable the optimal choice of risk-related therapy, remains a challenge. To improve neuroblastoma patient stratification, this study aimed to identify prognostic tumor DNA methylation biomarkers. Results: To identify genes silenced by promoter methylation, we first applied two independent genome-wide methylation screening methodologies to eight neuroblastoma cell lines. Specifically, we used re-expression profiling upon 5-aza-2'-deoxycytidine (DAC) treatment and massively parallel sequencing after capturing with a methyl-CpG-binding domain (MBD-seq). Putative methylation markers were selected from DAC-upregulated genes through a literature search and an upfront methylation-specific PCR on 20 primary neuroblastoma tumors, as well as through MBD- seq in combination with publicly available neuroblastoma tumor gene expression data. This yielded 43 candidate biomarkers that were subsequently tested by high-throughput methylation-specific PCR on an independent cohort of 89 primary neuroblastoma tumors that had been selected for risk classification and survival. Based on this analysis, methylation of KRT19, FAS, PRPH, CNR1, QPCT, HIST1H3C, ACSS3 and GRB10 was found to be associated with at least one of the classical risk factors, namely age, stage or MYCN status. Importantly, HIST1H3C and GNAS methylation was associated with overall and/or event-free survival. Conclusions: This study combines two genome-wide methylation discovery methodologies and is the most extensive validation study in neuroblastoma performed thus far. We identified several novel prognostic DNA methylation markers and provide a basis for the development of a DNA methylation-based prognostic classifier in neuroblastoma.Keywords
This publication has 67 references indexed in Scilit:
- Autosomal dominant polycystic kidney disease: Genetics, mutations and microRNAsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Epigenetic modifications and human diseaseNature Biotechnology, 2010
- Serial Transcriptome Analysis and Cross-Species Integration Identifies Centromere-Associated Protein E as a Novel Neuroblastoma TargetCancer Research, 2010
- Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high‐risk, neuroblastic tumor patientsInternational Journal of Cancer, 2009
- ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence dataBioinformatics, 2009
- Circulating Methylated-DCR2Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients withMYCNNonamplified NeuroblastomaClinical Cancer Research, 2008
- Differential Patterns of MicroRNA Expression in Neuroblastoma Are Correlated with Prognosis, Differentiation, and ApoptosisCancer Research, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005
- Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groupsCancer, 2002
- Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastomaMedical and Pediatric Oncology, 2001